Abstract 87P
Background
Systemic anticancer therapies have advanced beyond cytotoxic agents; checkpoint inhibitors have revolutionised cancer therapeutics and are now in routine use across multiple disease sites. The mechanism of action places patients at risk of immune-related (IR) side effects including IR colitis (IRC). The management of IRC is described in guidelines, however, in the UK access to some recommended therapies, particularly for steroid refractory IRC, including vedolizumab, remains unclear. We aimed to evaluate vedolizumab access and usage for IRC in UK hospitals.
Methods
We surveyed the use of vedolizumab across UK hospitals; the questionnaire was available between June and July 2024. Questions were developed to identify current practice focusing on preferred treatment guidelines, access to vedolizumab and treatment pathways. An electronic Microsoft Forms questionnaire was disseminated across 2 platforms; via email to all British Oncology Pharmacy Association (BOPA) members, and via presentation and QR code to Immuno-Oncology Clinical Network (IOCN) members for real-time completion. After removing duplicate hospital entries, data was analysed and grouped into themes.
Results
A total of 74 responses were received: 46% by pharmacists (n=34) and 31% by doctors (n=23). Duplicate hospital sites were subsequently combined, and the remaining 46 responses analysed. 65% hospitals (n=30) use ESMO or Clatterbridge cancer centre IRC guidelines. 93% hospitals (n=43) use infliximab 1st line in steroid refractory IRC. 57% hospitals (n=26) have used vedolizumab for 2nd line use, whilst 11% (n=5) hospitals have used it at any line of their IRC treatment pathway. 22% (n=10) hospitals have never used vedolizumab of which funding, experience, willingness to prescribe and lack of place in existing treatment pathways; are contributing factors.
Conclusions
Vedolizumab is used as a 2nd line option for IRC in over half of responding hospitals, however, there is disparity in its usage. The barriers to implementation appear to be primarily driven by funding, willingness to prescribe and experience. Real-world studies on the efficacy of Vedolizumab are warranted to further establish its place in the IRC pathway to recommend as a treatment option.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - Neoadjuvant adebrelimab combined with chemotherapy for adenocarcinoma of esophagogastric junction: A single-arm, single-center, phase II clinical trial
Presenter: Jinqiang Liu
Session: Poster Display session
Resources:
Abstract
147P - Serplulimab combined with chemotherapy in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: A single-arm phase II trial
Presenter: Zixiang Wu
Session: Poster Display session
Resources:
Abstract
148P - Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial
Presenter: JIE LIU
Session: Poster Display session
Resources:
Abstract
149P - Toripalimab and chemotherapy as first line combination in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: Kai Zhu
Session: Poster Display session
Resources:
Abstract
150P - Interim results of the multicenter phase II study on induction pembrolizumab plus chemotherapy followed by radiotherapy in locally advanced head and neck cancer
Presenter: Tatiana Antonova
Session: Poster Display session
Resources:
Abstract
151P - Anti-tumor T cell response and immunoselection under combined GARP:TGF-?1/PD-1 blockade
Presenter: Grégoire de Streel
Session: Poster Display session
Resources:
Abstract
152P - TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative
Presenter: Martin Forster
Session: Poster Display session
Resources:
Abstract
153P - Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study
Presenter: Cheng Xu
Session: Poster Display session
Resources:
Abstract
154P - Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 antagonistic antibody, as monotherapy in treatment-refractory non-small cell lung cancer (NSCLC)
Presenter: Aung Naing
Session: Poster Display session
Resources:
Abstract
155P - Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Presenter: Anne Chiang
Session: Poster Display session
Resources:
Abstract